The key idea is that P-gp recognition and transport tend to increase with the size and bulk of the molecule. A substrate that is heavier or more sterically bulky fits the P-gp binding pocket more readily and is more likely to be bound and actively effluxed. Lipophilicity helps a compound cross membranes, but on its own it doesn’t guarantee strong interaction with P-gp; a very lipophilic but small molecule may diffuse through without being pumped, while a bulky molecule can be a substrate even if not exceptionally lipophilic. So higher molecular weight raises the chances of P-gp–mediated efflux, making it the best single factor in this context.

During pregnancy, several physiologic changes shift how drugs distribute in the body and how much is bound to plasma proteins. The rise in plasma volume expands the intravascular and extracellular spaces, increasing the apparent volume of distribution (Vd), especially for hydrophilic drugs that distribute mainly into body fluids. At the same time, albumin levels fall due to hemodilution, reducing protein binding and increasing the fraction unbound (fu) for drugs that normally bind to albumin. Changes in tissue perfusion, with greater blood flow to many tissues and to the placenta, further influence how quickly and extent distribution occurs into tissues, also contributing to a larger Vd. Taken together, the combination of increased plasma volume, decreased albumin, and altered tissue perfusion best explains why both Vd can rise and fu can change during pregnancy. The other options describe changes that do not reflect the common pregnancy physiology and would not account for the SAMPLEobserved shifts in distribution and protein binding.

The volume of distribution is a hypothetical volume that would need to contain the total amount of drug in the body if the drug were present at the same concentration as in the plasma. It isn’t a real anatomical space; it’s a proportionality that links how widely a drug spreads from the bloodstream into tissues and fluids. This concept helps explain how a drug distributes after administration. A small Vd means the drug mostly stays in the plasma, while a large Vd indicates extensive distribution into tissues or binding to fatty tissues, bone, or proteins. Clinically, Vd is crucial for determining loading doses: the amount to give initially to achieve a target plasma concentration is obtained by multiplying the desired concentration by the Vd (loading dose = Vd × target Cp). It also helps interpret how a drug will behave after IV dosing: the observed plasma concentration depends on both Vd and clearance, with Vd shaping the distribution phase and how much of the dose remains in circulation at a given time. Why the other statements don’t fit: it is not the actual anatomical volume of body water and not used to calculate clearance; it is not simply body weight times plasma concentration; and it is not equal to the volume of plasma.

When distribution is perfusion-limited, the speed at which drug concentrations in tissue reach equilibrium with plasma is governed by how much blood flow delivers the drug to the tissue. Increasing perfusion means more drug is delivered to tissues per unit time, so tissue concentrations rise faster and reach the equilibrium point with plasma more quickly. In other words, a higher perfusion rate speeds up the approach to distribution equilibrium. If distribution were limited by tissue permeability rather than blood flow, changing perfusion would have less effect, but under perfusion-limited conditions the rate toward equilibrium increases with perfusion.